16 dicembre 2025 - Aggiornato alle 07:46
×

Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations

Redazione La Sicilia

11 Settembre 2019, 09:40